Vizomitin drops Ch. 5ml vial-cap.

$12.86

Vizomitin drops Ch. 5ml vial-cap.

30 in stock

Quantity:

SKU: 0211978889 Categories: , , Tag:

Description

Composition
Active substance:
1 mL contains: plastohinonildetsiltrifenilfosfoniya bromide (PDTF) 0.155 micrograms.
Excipients:
Benzalkonium chloride 0.1 mg, 2 mg hypromellose, sodium chloride 9 mg Sodium dihydrogen phosphate dihydrate 0.81 mg Sodium hydrogen phosphate dodecahydrate 1.16 mg Sodium hydroxide 1M to pH 6.3 – 7.3 Water for injection to 1 ml.
Description:
Transparent or slightly opalescent, colorless or slightly colored liquid.
Product form:
Eye drops a concentration of 0.155 mg / ml in polyethylene vials with 5 ml of congestion – droppers and screw cap. Each vial with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to the drug, the age of 18 years.
Indications
Syndrome of “dry eye.”
The initial stage of age-related cataract.
Interaction with other drugs
If necessary, can be used concomitantly with other eye drops. In this case, the interval between the instillation must be at least 5 minutes.
Overdose
Data on overdose by topical application no.
pharmachologic effect
Pharmacological group:
Keratoprotektornoe means.
Anti-oxidant agent.
Pharmacodynamics:
Plastohinonildetsiltrifenilfosfoniya bromide (PDTF) plastoquinone is derived which, via a linker chain (C10) is associated with residual triphenylphosphine. PDTF at low (nanomolar) concentrations shows a high antioxidant activity. Also has a stimulating effect on the process slezoproduktsii, epithelialization, enhances the tear film stability.
One reason for the development of senile cataract is the damaging effect of ultraviolet radiation, which initiates the photo-oxidation processes which lead to denaturation of the main structural component of the lens – crystallins. First eye tissue protection against ultraviolet radiation is the lacrimal fluid that absorbs ultraviolet light in the range 240-320 nm and neutralizes its components due to the antioxidant activity of the lachrymal fluid. According to preclinical studies, protivokataraktalnoe Vizomitin® drug action associated with an increased level of expression of core protein lens alpha-crystallin, lens epithelium restoration and activation energy processes in it. According to a clinical study in patients with age-related cataracts, use the drug Vizomitin®, was an increase in the antioxidant activity of tears.
Pharmacokinetics:
pharmacokinetic studies in humans have been conducted. In preclinical animal studies PDTF distribution in organs and tissues occurred within 48 h after intravenous and intragastric administration. It was found that PDTF present in the highest concentrations in renal tissue, liver and heart for 1 hour after administration. PDTF relatively quickly subjected to enzymatic cleavage and covalent binding with proteins.
Pregnancy and breast-feeding
Adequate controlled studies in pregnant and lactating women have not been conducted. Not recommended for use during pregnancy. If necessary, the appointment during lactation in the period of treatment should stop breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions.
From the senses: possible transient burning sensation and cramps in her eyes after instillation.
special instructions
The effect on the ability of control of vehicles and mechanisms
If after treatment there is a short-term blurred vision, until his recovery is not recommended to drive and engage in activities that require high concentration.
Storage conditions
In the dark place at a temperature of from 2-80S.
After opening, the vial is kept in the dark place at a temperature 2-80S; use within 1 month.
Keep out of the reach of children.
Dosing and Administration
Syndrome of “dry eye”: 1-2 drops into the conjunctival sac of the drug 3 times a day. Duration of treatment is established doctor depending on the severity of the disease.
Initial stage senile cataract: 1-2 drops into the conjunctival sac of the drug 3 times a day. Duration of treatment – 6 months. During therapy with an ophthalmologist must observation to evaluate the degree of progression of the disease and necessity of continuation of the conservative therapy.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

MITOTEH

There are no reviews yet.

Add your review